May 7, 2024 – Talk Bio

Intellectual property landscape around prime editing

12 months ago talkbio0Tagged CRISPR, Patent infringement, patent litigation, Prime Editing

Intellectual Property Landscape Around Prime Editing Prime editing, a revolutionary genome editing technology, has been at the forefront of significant intellectual property developments and patent disputes. This technology, which allows for precise DNA edits without the need for double-strand breaks, was developed by Dr. David Liu and his team at the Broad Institute and Harvard […]

What is the difference between prime editing and CRISPR/Cas9

12 months ago talkbio0Tagged CRISP, Prime Editing

The difference between Prime Editing and CRISPR/Cas9 lies in their mechanisms of editing DNA, their efficiency, precision, and the types of genetic modifications they can achieve. Mechanism of Editing Efficiency and Precision Types of Genetic Modifications In summary, while both Prime Editing and CRISPR/Cas9 are groundbreaking genome editing tools, Prime Editing offers a more precise […]

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement

12 months ago talkbio0Tagged AstraZeneca, Biotechnology, Cell Therapy, Cellectis, development aspects, Discover, gene therapy, Health care facility, innovation, Investments, Medical Research activity, Papillary thyroid carcinoma, Partnership, stake

AstraZeneca, Cellectis, cell therapy, gene therapy, partnership, stake, discovery, pact, biotechnology, healthcare, investment, innovation, medical research, therapeutic development.

GlycoMimetics’ Uproleselan Fails to Meet Primary Endpoint in Leukemia Clinical Trial

12 months ago talkbio0Tagged Clinical Trials, GlycoMimetics, leukemia, Primary Endpoint, Stock Market Reaction, Uproleselan

GlycoMimetics, Uproleselan, Leukemia, Clinical Trial, Primary Endpoint, Stock Market Reaction

Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief

12 months ago talkbio0Tagged Andrew Baum, Chief, Citi, Drug Industry, Leadership Change, Pfizer, Strategic Planning, Strategy

Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.

Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment

12 months ago talkbio0Tagged Cardiovascular Diseases, Chiesi, Clinical Trials, Collaboration, Drug Development, GD-001, Gossamer, Investments, Pulmonary Hypertension

Chiesi, Gossamer, pulmonary hypertension, drug development, investment, collaboration, GD-001, clinical trials, cardiovascular diseases.

Novo, Gates, and Wellcome Join Forces with $300 Million Initiative to Tackle Global Infectious Diseases

12 months ago talkbio0Tagged Collaboration, Communicable Diseases, development aspects, Global Health, Holdings, Melinda, Microbicides, pandemic preparedness, research, Resistance (Psychotherapeutic), Trust (Social Behavior), Wellcome

Novo Holdings, Bill & Melinda Gates Foundation, Wellcome Trust, infectious diseases, global health, pandemic preparedness, antimicrobial resistance, research and development, funding, collaboration.